Guidance for Industry (GFI): Expedited Programs for Serious Conditions-Drugs and Biologics

ICR 201802-0910-008

OMB: 0910-0765

Federal Form Document

Forms and Documents
Document
Name
Status
Supporting Statement A
2018-02-10
ICR Details
0910-0765 201802-0910-008
Historical Active 201703-0910-010
HHS/FDA CDER
Guidance for Industry (GFI): Expedited Programs for Serious Conditions-Drugs and Biologics
Revision of a currently approved collection   No
Regular
Approved without change 04/27/2018
Retrieve Notice of Action (NOA) 02/13/2018
  Inventory as of this Action Requested Previously Approved
04/30/2021 36 Months From Approved 05/31/2020
514 0 193
34,730 0 10,310
0 0 0

This ICR collects information from sponsors and applicants who wish to obtain a priority review designation or breakthrough therapy designation. Respondents to the collection are manufacturers or sponsors of drug and/or biologic products.

US Code: 21 USC 356 Name of Law: FFDCA; Fast track products
  
None

Not associated with rulemaking

  82 FR 51846 11/08/2017
83 FR 5428 02/07/2018
No

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 514 193 0 0 321 0
Annual Time Burden (Hours) 34,730 10,310 0 0 24,420 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
No
No
Upon approval of this ICR, OMB Control No. 0910-0389 will be discontinued.

$0
No
    No
    No
No
No
No
Uncollected
Domini Bean 301 796-5733 domini.bean@fda.hhs.gov

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
02/13/2018


© 2024 OMB.report | Privacy Policy